CU20170148A7 - Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados - Google Patents

Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados

Info

Publication number
CU20170148A7
CU20170148A7 CU2017000148A CU20170148A CU20170148A7 CU 20170148 A7 CU20170148 A7 CU 20170148A7 CU 2017000148 A CU2017000148 A CU 2017000148A CU 20170148 A CU20170148 A CU 20170148A CU 20170148 A7 CU20170148 A7 CU 20170148A7
Authority
CU
Cuba
Prior art keywords
egfr
growth factor
epidermal growth
fragments
receiver
Prior art date
Application number
CU2017000148A
Other languages
English (en)
Other versions
CU24558B1 (es
Inventor
Monzón Kalet León
Dorantes Gertrudis Rojas
Cabado Yaima Tundidor
Original Assignee
Ct Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Inmunologia Molecular filed Critical Ct Inmunologia Molecular
Priority to CU2017000148A priority Critical patent/CU24558B1/es
Priority to CA3082759A priority patent/CA3082759A1/en
Priority to PCT/CU2018/050004 priority patent/WO2019105492A1/es
Priority to KR1020207018489A priority patent/KR102708617B1/ko
Priority to CN201880077704.5A priority patent/CN111417654B/zh
Priority to MYPI2020002415A priority patent/MY201635A/en
Priority to BR112020010075-7A priority patent/BR112020010075A2/pt
Priority to JP2020547282A priority patent/JP7396992B2/ja
Priority to NZ765527A priority patent/NZ765527B2/en
Priority to US16/767,356 priority patent/US11718676B2/en
Priority to MX2020005490A priority patent/MX2020005490A/es
Priority to AU2018377764A priority patent/AU2018377764B2/en
Priority to EP18830130.3A priority patent/EP3719037A1/en
Priority to EA202091328A priority patent/EA202091328A1/ru
Priority to SG11202004746VA priority patent/SG11202004746VA/en
Priority to TW107142095A priority patent/TWI820058B/zh
Priority to ARP180103458A priority patent/AR113843A1/es
Publication of CU20170148A7 publication Critical patent/CU20170148A7/es
Priority to ZA2020/03866A priority patent/ZA202003866B/en
Publication of CU24558B1 publication Critical patent/CU24558B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)

Abstract

<p>Esta invención proporciona nuevos anticuerpos (Ac) y fragmentos que reconocen Ia región extracelular del receptor del factor de crecimiento epidérmico (EGFR) humano con una mayor afinidad que el Ac nimotuzumab, por lo que pueden reconocer con mayor eficiencia, líneas con mediana expresión del EGFR. La presente invención se relaciona además, con las composiciones farmacéuticas que comprenden como principal activo los Acs y fragmentos divulgados y su uso en Ia terapia de tumores con expresión del EGFR. Además, los Acs y fragmentos divulgados son útiles cuando están enlazados a un radioisótopo o fluoróforo en Ia localización de tumores que presenten el EGFR. Adicionalmente, se pueden utilizar en direccionalizar Ia respuesta inmune a las células tumorales EGFR positivas cuando se fusionan a proteínas o dominios proteicos de interés inmunológico.<br /> </p>
CU2017000148A 2017-11-28 2017-11-28 Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados CU24558B1 (es)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CU2017000148A CU24558B1 (es) 2017-11-28 2017-11-28 Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados
US16/767,356 US11718676B2 (en) 2017-11-28 2018-11-20 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
MX2020005490A MX2020005490A (es) 2017-11-28 2018-11-20 Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidermico y sus fragmentos derivados.
KR1020207018489A KR102708617B1 (ko) 2017-11-28 2018-11-20 표피성장인자 수용체에 대한 증가된 친화도를 가지는 항체 및 이의 단편
CN201880077704.5A CN111417654B (zh) 2017-11-28 2018-11-20 具有增加的对于表皮生长因子受体的亲和力的抗体及其衍生片段
MYPI2020002415A MY201635A (en) 2017-11-28 2018-11-20 Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments
BR112020010075-7A BR112020010075A2 (pt) 2017-11-28 2018-11-20 anticorpos de afinidade aumentada para o receptor de fator de crescimento epidérmico e seus fragmentos derivados
JP2020547282A JP7396992B2 (ja) 2017-11-28 2018-11-20 上皮成長因子受容体に対する親和性が増加した抗体およびそれに由来するフラグメント
NZ765527A NZ765527B2 (en) 2018-11-20 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
CA3082759A CA3082759A1 (en) 2017-11-28 2018-11-20 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
PCT/CU2018/050004 WO2019105492A1 (es) 2017-11-28 2018-11-20 Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados
AU2018377764A AU2018377764B2 (en) 2017-11-28 2018-11-20 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
EP18830130.3A EP3719037A1 (en) 2017-11-28 2018-11-20 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
EA202091328A EA202091328A1 (ru) 2017-11-28 2018-11-20 Антитела с повышенной аффинностью к рецептору эпидермального фактора роста и происходящие из них фрагменты
SG11202004746VA SG11202004746VA (en) 2017-11-28 2018-11-20 Antibodies of increased affinity for the epidermal growth factor receptor and its derived fragments
TW107142095A TWI820058B (zh) 2017-11-28 2018-11-26 對表皮生長因子受體具有增加的親和性之抗體及其衍生之片段
ARP180103458A AR113843A1 (es) 2017-11-28 2018-11-27 Anticuerpos de afinidad incrementada por el receptor del factor de crecimiento epidérmico y sus fragmentos derivados
ZA2020/03866A ZA202003866B (en) 2017-11-28 2020-06-25 Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2017000148A CU24558B1 (es) 2017-11-28 2017-11-28 Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados

Publications (2)

Publication Number Publication Date
CU20170148A7 true CU20170148A7 (es) 2019-07-04
CU24558B1 CU24558B1 (es) 2021-12-08

Family

ID=64959051

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2017000148A CU24558B1 (es) 2017-11-28 2017-11-28 Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados

Country Status (17)

Country Link
US (1) US11718676B2 (es)
EP (1) EP3719037A1 (es)
JP (1) JP7396992B2 (es)
KR (1) KR102708617B1 (es)
CN (1) CN111417654B (es)
AR (1) AR113843A1 (es)
AU (1) AU2018377764B2 (es)
BR (1) BR112020010075A2 (es)
CA (1) CA3082759A1 (es)
CU (1) CU24558B1 (es)
EA (1) EA202091328A1 (es)
MX (1) MX2020005490A (es)
MY (1) MY201635A (es)
SG (1) SG11202004746VA (es)
TW (1) TWI820058B (es)
WO (1) WO2019105492A1 (es)
ZA (1) ZA202003866B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117500523A (zh) * 2021-06-14 2024-02-02 免疫分子中心 针对表皮生长因子受体的单克隆抗体治疗患有低氧血症型急性呼吸衰竭的患者的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
JPWO2006090930A1 (ja) * 2005-02-28 2008-07-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の新規併用
EP2190878A1 (en) * 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
MX349622B (es) * 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
US8691231B2 (en) * 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
AU2013229786B2 (en) * 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
BR112015008251B1 (pt) * 2012-10-12 2023-09-26 Medimmune Limited Pirrolobenzodiazepinas, conjugados destas, composição e composição farmacêutica compreendendo os conjugados, uso dos conjugados para o tratamento de uma doença proliferativa e método para preparar os conjugados
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
CN104530237B (zh) * 2014-12-31 2017-09-05 百泰生物药业有限公司 抗Her1的治疗性抗体
AU2016282723B2 (en) * 2015-06-22 2021-09-23 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (ADCs) and antibody prodrug conjugates (APDCs) with enzymatically cleavable groups
CN108348602A (zh) * 2015-07-27 2018-07-31 伊诺西麦博个人独资有限公司 采用针对表皮生长因子受体（egfr）的单克隆抗体治疗被诊断患有胰腺导管腺癌的患者

Also Published As

Publication number Publication date
NZ765527A (en) 2024-02-23
KR20200090236A (ko) 2020-07-28
EA202091328A1 (ru) 2020-09-17
CU24558B1 (es) 2021-12-08
TWI820058B (zh) 2023-11-01
EP3719037A1 (en) 2020-10-07
BR112020010075A2 (pt) 2020-10-13
CA3082759A1 (en) 2019-06-06
WO2019105492A1 (es) 2019-06-06
ZA202003866B (en) 2022-06-29
SG11202004746VA (en) 2020-06-29
MX2020005490A (es) 2020-09-03
US11718676B2 (en) 2023-08-08
AU2018377764B2 (en) 2022-09-29
AR113843A1 (es) 2020-06-17
JP2021504484A (ja) 2021-02-15
KR102708617B1 (ko) 2024-09-25
US20210002375A1 (en) 2021-01-07
CN111417654A (zh) 2020-07-14
AU2018377764A1 (en) 2020-07-09
CN111417654B (zh) 2023-11-10
MY201635A (en) 2024-03-06
JP7396992B2 (ja) 2023-12-12
TW201932485A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
MX2023014569A (es) Anticuerpos anti-sirpa.
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
CY1122669T1 (el) Σκευασματα αντισωματων αντισκληροστινης υψηλης συγκεντρωσης
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201600190A1 (ru) Анти-prlr антитела и их применение
PE20190126A1 (es) Proteinas de union y metodos de uso de las mismas
PH12017502390A1 (en) Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof
CU20180062A7 (es) Anticuerpos neutralizadores del virus de inmunodeficiencia humana
UY34995A (es) Formulaciones de anticuerpo y proteína
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
MX373280B (es) Anticuerpos anti-egfrviii y usos de los mismos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2019007554A (es) Proteínas de uníon al antígeno anti-neuropilina, y sus métodos de uso.
EA201590085A1 (ru) Антитела анти-egfr и их применение
TR201809571T4 (tr) Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
MX380520B (es) Anticuerpos receptores de antitransferina y métodos de uso.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20250392A1 (es) Anticuerpos a la alfa-sinucleina y usos de los mismos
PE20130324A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
UA118354C2 (uk) Антитіло до рецептора колонієстимулювального фактора (кфс-1r)
PL422231A1 (pl) Komórki immunologiczne CAR do leczenia nowotworów